Alexion's successor to Soliris hits co-primary endpoints in a pivotal, but can't surpass the big blockbuster
With a group of rivals pressing in from every side, looking to capture a piece of Alexion’s $ALXN blockbuster market for the rare disease trendsetter …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
